KE News & Events

Reports Q2 revenue $341.3M, consensus $339.34M. Commenting on today's announcement, Richard D. Phillips, Chief Executive Officer, stated, "I'm pleased with the results for the second quarter and our updated guidance for fiscal 2026. Sales in Q2 were in line with expectations, highlighted by another quarter of strong double-digit year-over-year growth in the medical vertical, margins improved compared to the same period last year, and cash from operations was positive for the eighth consecutive quarter."

Consensus $1.4B. Adjusted operating income is estimated to be 4.2% - 4.5% of net sales versus the prior estimate of 4.0% - 4.25% The guidance for capital expenditures did not change with a range of $50 - $60 million.

As part of today's announcement, the Company reiterated its guidance for fiscal year 2026 with net sales expected to be in the range of $1,350 - $1,450 million and adjusted operating income of 4.0% - 4.25% of net sales. Capital expenditures are estimated to be $50 - $60 million.